

Special Issue

Diabetes Mellitus: Current Research and Future Perspectives, 2nd Edition

Message from the Guest Editors

The heterogeneity in age at onset and clinical presentation within the same form of diabetes, differences in the response to treatments in patients with the same phenotype, and the variability in the course of the disease require personalized management. In the last 10 years, genetic, metabolomic, immunologic, and other sophisticated tests have become less expensive and more widespread; therefore, it is expected that precision medicine will become increasingly applied to diabetes care. This Special Issue of *Journal of Personalized Medicine* aims to highlight the current state of precision medicine applied to diabetes to show some of the latest findings and future perspectives and integrate expertise from basic science, clinical, and population-based approaches. Topics of interest include novel insights into gene testing, polymorphisms and bioinformatics, metabolites and intestinal microbiome analysis, as well as their association with the risk of disease, drug metabolism, or disease complications.

Guest Editors

Dr. Roberto Franceschi


Pediatric Unit, S. Chiara Hospital, 38122 Trento, Italy

Dr. Evelina Maines

Division of Pediatrics, S. Chiara General Hospital, APSS Trento, 38122 Trento, Italy

Deadline for manuscript submissions

30 March 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/198184

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).